BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11257407)

  • 1. Adjuvants designed for veterinary and human vaccines.
    Aucouturier J; Dupuis L; Ganne V
    Vaccine; 2001 Mar; 19(17-19):2666-72. PubMed ID: 11257407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of water-in-oil-in-water multiple emulsion and microemulsion as potential adjuvants for immunization with rabies antigen.
    Leclercq SY; dos Santos RM; Macedo LB; Campos PC; Ferreira TC; de Almeida JG; Seniuk JG; Serakides R; Silva-Cunha A; Fialho SL
    Eur J Pharm Sci; 2011 Aug; 43(5):378-85. PubMed ID: 21627989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis.
    Aucouturier J; Deville S; Perret C; Vallée I; Boireau P
    Parasite; 2001 Jun; 8(2 Suppl):S126-32. PubMed ID: 11484335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
    Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
    Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
    Baldridge JR; Crane RT
    Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEPPIC vaccine adjuvants for poultry.
    Dupuis L; Ascarateil S; Aucouturier J; Ganne V
    Ann N Y Acad Sci; 2006 Oct; 1081():202-5. PubMed ID: 17135512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of oil adjuvants in therapeutic vaccines.
    Aucouturier J; Ascarateil S; Dupuis L
    Vaccine; 2006 Apr; 24 Suppl 2():S2-44-5. PubMed ID: 16823921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle.
    Romera SA; Hilgers LA; Puntel M; Zamorano PI; Alcon VL; Dus Santos MJ; Blanco Viera J; Borca MV; Sadir AM
    Vaccine; 2000 Aug; 19(1):132-41. PubMed ID: 10924795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in vaccine delivery systems.
    O'Hagan DT
    Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The path to a successful vaccine adjuvant--'the long and winding road'.
    O'Hagan DT; De Gregorio E
    Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine adjuvants: smart components to boost the immune system.
    Bastola R; Noh G; Keum T; Bashyal S; Seo JE; Choi J; Oh Y; Cho Y; Lee S
    Arch Pharm Res; 2017 Nov; 40(11):1238-1248. PubMed ID: 29027637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oil-based emulsion vaccine adjuvants.
    Schijns VEJC; Strioga M; Ascarateil S
    Curr Protoc Immunol; 2014 Aug; 106():2.18.1-2.18.7. PubMed ID: 25081910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical and Immunological Characteristics of Aluminum-Based, Oil-Water Emulsion, and Bacterial-Origin Adjuvants.
    Martiñón S; Cisneros A; Villicaña S; Hernández-Miramontes R; Mixcoha E; Calderón-Vargas P
    J Immunol Res; 2019; 2019():3974127. PubMed ID: 31205956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine adjuvants.
    Macy DW
    Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):206-11. PubMed ID: 9283246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
    Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
    Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the current status of oil adjuvants in foot--and--mouth disease vaccines.
    McKercher PD; Graves JH
    Dev Biol Stand; 1976; 35():107-12. PubMed ID: 198275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sucrose fatty acid sulphate esters as novel vaccine adjuvant.
    Hilgers LA; Blom AG
    Vaccine; 2006 Apr; 24 Suppl 2():S2-81-2. PubMed ID: 16823938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.
    Petrovsky N
    Drug Saf; 2015 Nov; 38(11):1059-74. PubMed ID: 26446142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manufacture of Oil-in-Water Emulsion Adjuvants.
    Haensler J
    Methods Mol Biol; 2017; 1494():165-180. PubMed ID: 27718193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.